Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 2Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 6lanreotide 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Capecitabine 3surufatinib 2pasireotide 2fluorodopa F 18 2Temozolomide 2Lutetium-177 2Lutetium 2Introns 2Ga(III)-DOTATOC 2telotristat ethyl 1pembrolizumab 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Watchful Waiting 1Sunitinib 1Specimen Handling 1Somatostatin 1Serotonin 1Salts 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Phantoms, Imaging 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Phantoms, Imaging × NET × Clear all
NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡